Resources

Visit this portal to explore Alfa Cytology’s collection of brochures, posters and flyers. Sort by literature type or category to find the materials that best suit your needs.

Search
Downloads
Cancer Types
Solutions
Solutions

How to Select the Right Service Provider for Cancer Therapy Development

Choosing a service provider for cancer-therapy development demands scrutiny of scientific depth, end-to-end capabilities, and a proven culture of data-driven execution. Backed by extensive oncology expertise and integrated preclinical platforms, Alfa Cytology is a specialized partner ready to advance your drug-development initiatives with confidence.

Factors to Consider When Choosing A CRO

Selecting a contract research organization hinges on assessing its scientific expertise, technology platforms, and quality systems to ensure reliable, reproducible data. Equally important are transparent pricing, responsive communication, and a proven record of delivering studies on time and within scope.

Experiences

Look for CROs with experiences.

Capabilities

Evaluate the CRO’s capabilities.

Expertise

Consider regulatory expertise.

Quality

Check for quality management.

Cost

Choose to compare competitive prices.

Reputation

Check references and reputation.

Diverse Platforms for All Cancer Therapies

Whether you are refining early hits or completing IND-enabling studies, our seasoned experts and state-of-the-art infrastructure keep your program advancing with confidence. Leveraging integrated platforms and rigorous project management, we streamline every step toward IND submission—and position your therapy for the milestones that follow.

Discovery

  • Small Molecules Platform
  • Therapeutic Antibody Platform
  • Cell and Gene Therapy Platform
  • Vaccine Platform
  • Peptide Platform

Pharmacology Evaluation

  • Target-specific Assays
  • Efficacy Evaluation Assays
  • DMPK/ ADME
  • Drug Toxicity Evaluation Assay

IND Enabling

Our Capabilities at A Glance

From initial target validation to full IND-enabling packages, we integrate complementary platforms that accelerate every phase of preclinical drug discovery. The summary below distills our core competencies, charting a clear path from molecular concept to in-vivo proof of principle.

Target Discovery

  • SiRNA/ Crispr
  • mRNA and Protein Expression
  • Signaling Pathway Assay Development
  • Biomarker Analysis

Hit Identification

  • AI-guided Hit Design
  • Target-specific Enzymatic Assays
  • 2D Cell-based Assays
  • 3D Cell-based Assays
  • In Vivo Efficacy Evaluation

Lead Optimization

  • Functional Analysis
  • Selectivity Test
  • Counter Assay
  • MOA Study
  • PK/PD Studies
  • Efficacy Evaluation

IND Enabling

  • Toxicology Evaluation
  • Safety Pharmacology
  • In Vivo DMPK
  • In Vitro ADME
  • Efficacy Evaluation

Powered by deep oncology expertise and state-of-the-art preclinical platforms, Alfa Cytology is ready to propel your cancer-therapy programs with scientific rigor and efficiency. If you have any questions or would like to explore tailored solutions, please reach out to our team at your convenience.